DaVita Inc. (NYSE:DVA) Shares Bought by Treasurer of the State of North Carolina

Treasurer of the State of North Carolina lifted its holdings in shares of DaVita Inc. (NYSE:DVAFree Report) by 1.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,737 shares of the company’s stock after acquiring an additional 234 shares during the quarter. Treasurer of the State of North Carolina’s holdings in DaVita were worth $2,591,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Hanseatic Management Services Inc. acquired a new stake in DaVita in the third quarter valued at approximately $36,000. Principal Securities Inc. acquired a new stake in DaVita during the 4th quarter valued at $37,000. GAMMA Investing LLC purchased a new stake in DaVita during the 4th quarter worth $60,000. Quest Partners LLC acquired a new position in DaVita in the 4th quarter worth $74,000. Finally, Tacita Capital Inc purchased a new position in DaVita in the 3rd quarter valued at about $118,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Price Performance

Shares of DVA opened at $143.84 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. The firm has a market cap of $12.61 billion, a price-to-earnings ratio of 16.35, a PEG ratio of 1.11 and a beta of 0.96. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $147.93. The stock has a 50 day moving average of $136.69 and a 200-day moving average of $122.22.

DaVita (NYSE:DVAGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The firm had revenue of $3.07 billion during the quarter, compared to analyst estimates of $3.03 billion. During the same quarter in the previous year, the firm earned $1.58 earnings per share. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. As a group, analysts forecast that DaVita Inc. will post 9.62 EPS for the current year.

Insider Buying and Selling

In other news, Director Barbara J. Desoer sold 5,030 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $138.81, for a total transaction of $698,214.30. Following the completion of the transaction, the director now directly owns 10,954 shares of the company’s stock, valued at $1,520,524.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.00% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DVA. Truist Financial lifted their target price on DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, May 15th. StockNews.com raised DaVita from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 31st. UBS Group raised their price target on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Finally, Barclays upped their price target on shares of DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a report on Monday, May 6th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $144.67.

Get Our Latest Stock Analysis on DVA

DaVita Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Further Reading

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVAFree Report).

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.